Abstract
BACKGROUND Thrombolysis should be offered to all patients with Ischemic stroke who meets the selection criteria. It involves the intravenous infusion of tissue plasminogen activator tPA, which in our Trust is Alteplase. The rationale is to break down the clot in the blood vessel and restore blood flow to save the area of penumbra AIMS. To determine the prevalence of adverse events. To highlight the different types of adverse events. To find out if there is aggregation of these adverse events to certain period of the day or months.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call